The past 25 CT shows soft tissue lesions larger than 0.5-1.Ocm and is used mainly in the brain, mediastinum and abdomen but is also applicable to lungs and bone. In cancer the primary diagnosis has usually been made; CT is used for staging particularly in detecting unsuspected stage III and IV disease, especially lymphadenopathy and pulmonary metastases and usually upgrades the staging. The size of the tumour can be accurately determined as can the volume. In the brain, a tumour can be distinguished from surrounding oedema. Incidental or consequential pathology is frequently uncovered. 21 "abnormal areas" were demonstrated in seven and of these, four could not be shown by other techniques. Uptake could not be attributable to free iodide. Tumour localisation has also been obtained in two patients with islet-cell tumours of the pancreas (diameter 1.5 and 2cm) using a polyclonal anti-insulin. Monoclonal antibodies have also been used in several centres, so far with similar localising ability. Pilot studies have also been undertaken with positron emitting isotopes for thyroid identification using two facing integrated wire grid detectors. 1958-1970 and followed for a minimum period of 7 years, paraffin sections were stained by a peroxidase antiperoxidase technique using a primary antibody directed against the fi subunit of human chorionic gonadotrophin. The sections were examined independently by two observers. The incidence of syncytial giant cells was greater than commonly reported, and no significant difference was observed between tumours of different pathological stages (see Table) . A higher proportion of patients with stage P2 lesions who died of the disease had tumours containing HCG + ve cells, but these figures did not attain statistical significance. Human breast tumours may produce substantial amounts of prostaglandin-like material (Bennett et al., (1975 ), Lancet, i, 1218 Rolland, (1980) CIC concentrations were measured in 31 patients with known disease, and 11 had elevated CIC concentrations. Of 15 patients followed serially after apparently curative resection, 7 showed clinical recurrence of disease and IC were elevated in 5 of these whilst CEA was elevated in 2. CIC were also raised in 2 patients who remained clinically well. CEA predicted clinical relapse in 4/7 patients, and in 2 of these CIC levels were elevated prior to CEA.
To investigate the possibility that CIC found in these patients contained CEA as an antigen component a new assay, based on perchloric acid extraction of PEG precipitated and acid dissociated complexed CEA was employed. CEA-IC were shown to be present in model complexes but were not found in 30 patients with known disease, 6 of which were examined serially.
CIC may augment CEA as an indicator of disease recurrence in colorectal cancer but may also be elevated in patients without known disease, probably due to the non-specificity of current CIC assays. An antigen directed CEA-IC assay suggested that the CIC detected did not contain CEA. Polyclonal IgG antibodies against the idiotypic surface immunoglobulin (id) on lymphoma cells from two patients with established B-cell lymphoma were raised in sheep by a previously described method (Stevenson et al. (1980) , J. Exp. Med., 152, 1484. These anti-idiotypic antibodies (anti-id) were then used to monitor disease progress in two ways over a one year period: (i) The id-bearing lymphoma cells in blood and bone marrow were identified and counted using fluoresceinated anti-id.
(ii) Using the ELISA technique small quantities of circulating free idiotype could be identified and quantitated in the serum. In one patient with predominantly bone marrow disease in apparent remission there was a tenfold increase in free idiotype levels (to c.50 jug ml-1) and a 3-fold increase in id-bearing lymphoid cells in the blood prior to overt haematological relapse. At relapse 40% of the bone marrow cells and 90% of blood cells were id-bearing. A short course of oral chemotherapy produced clinical remission and a corresponding decrease in both parameters which have been further monitored over a 6-month period off treatment. In the second patient, with progressive nodal disease, id-bearing cells (15% of lymphoid cells) were identified in a morphologically normal bone marrow specimen. The (2 pg ml-1), 4-hydroperoxycyclophosphamide (2 pg ml -), vincristine (0.1 pg ml -) and prednisolone (0.5 pg ml -1).
Other drugs are also under investigation. The great susceptibility of rapidly growing tissues to carcinogens is well documented. The differential susceptibility is often reflected in the striking differences between the effects of various xenobiotics on pregnant or lactating rats, and on their offspring. The latter may become affected by exposing the mother to doses of noxious agents, which leave the adult unscathed, as was first demonstrated using the hepatotoxic and hepatocarcinogenic pyrrolizidine alkaloids. In continuation of these studies, other substances were used which include the carcinogenic secondary metabolites of Fusarium. When relatively large doses of the oestrogenic zearalenone. were given, either singly or combined with the trichothecene, T-2 toxin, to pregnant and/or lactating white rats, various tumours, benign and malignant, were found both in the treated mother-rat, and also in the offspring, male and female. (NRS) , calf serum, and normal human serum were tested in this system at 0.1-20%. All elicited DNA-S at 0.1-1.0% similar to that produced by 3H alone. However, above 3%, the only observable effect was an inhibition of DNA-S compared to 3H alone. Human plasma was similar to human serum, but human platelet-derived growth factor consistently inhibited DNA-S at 1.25-lOjugml-'. No difference was observed when NRS was compared to serum from rats containing regenerating livers at 1-36 h after partial hepatectomy. However, the serum from rats which were fed the hepatocarcinogen 2-AAF induced a 4-fold increase in the DNA-S compared to NRS, starting at 1 week after carcinogen administration. The 105,000 x g supernatant of 2-AAF livers also increased the level of DNA-S in the test hepatocytes compared to the similar extract from normal liver. These presumptive tumour growth factor(s) are now being further characterized.
Gamma glutamyl transpeptidase (yGT) found in the bile duct epithelium in normal adult rat liver, appears in foci of hepatocytes (so-called preneoplastic lesions) in animals exposed to one or more of a wide range of carcinogens. Among the proposed functions of yGT in normal liver are involvement in maintenance of intracellular glutathione levels and also in breakdown of glutathione conjugates in the first stage of mercapturic acid formation. The function of the enzyme in preneoplastic foci is poorly understood, although such hepatocytes may be more resistant to cytotoxic effects of the carcinogen. In the present study bile was collected from control adult male Fischer 344 rats and from animals fed a diet containing 4ppm AFB1 for at least 10 weeks. Fifteen mins before cannulation some animals received 11 mg AT 125 i.p. and immediately prior to bile collection some animals from each group received i.v. 5 jiM kg-1 AFB1. yGT activity was examined histochemically in liver and quantitatively in liver and bile. The enzyme was present in the bile duct epithelium in control animals and also in numerous foci in fed animals (5-lOx control levels). yGT activity could be measured in bile from control and fed animals but no particular pattern emerged. In animals treated with AT 125, a specific inhibitor of yGT, no. enzyme activity was visible histochemically in any lobe of the liver and no activity could be measured in liver homogenates or in bile. yGT activity was also measured in female rats (which are more resistant to toxic and carcinogenic effects of AFB1) and found on average to be 2 x that of males, present in hepatocytes as well as bile ducts. These animals were then used to study the effect of altered yGT activity, particularly in hepatocytes, on the pattern of AFB1-conjugates excreted into bile following a single i.v. dose of the carcinogen as described in the next abstract. In man and the rat with malignant disease folate metabolism alters so as to reduce folate breakdown by scission and to increase the proportion of folates present as 10-formyltetrahydrofolate derivatives. Thus the concentration of the folate coenzymes crucial for the synthesis of purines and thymidylate for RNA and DNA increases. In oestrogensensitive human breast tumours but not in human gut tumours dihydropteridine reductase activity, an enzyme reducing folate scission, is significantly increased compared to adjacent apparently normal tissue. Oral administration of diethylstilboestrol to female rats significantly reduces folate breakdown and greatly increases the proportion of 10-formyltetrahydrofolate. Thus oestrogen appears to alter folate metabolism to a pattern required for proliferating tissue. Anti-oestrogen therapy of breast tumours may act by altering folate metabolism.
